scholarly journals Infective endocarditis in patients with solid organ transplantation. A nationwide study

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
M Martinez-Selles ◽  
M Valerio ◽  
M.C Farinas ◽  
H Rodriguez-Abella ◽  
M.L Navarro ◽  
...  

Abstract Background An increase in nosocomial and health care-related infective endocarditis (IE) has been described. Solid organ transplantation (SOT) implies immunosuppression and frequent health care contact. Our aim was to compare characteristics of patients with IE and SOT against those without SOT. Methods We used data from the Spanish Collaboration on Endocarditis obtained during the period 2008–2018. Results We identified 4794 cases of IE, 85 (1.8%) in SOT (56 kidney, 18 liver, 8 heart, 3 lung). Thirteen patients had other types of transplantation (bone marrow, hematopoietic precursors, and cornea) and were excluded from the analysis. Compared with patients without SOT, patients with SOT had a higher median age (69 vs. 61 years, p<0.001), more comorbidities (mean age-adjusted Charlson index 5.7±2.9 vs. 4.9±2.9, p=0.004), a lower prevalence of native valvular heart disease (29.4 vs. 45.4%, p=0.003), more in-hospital and healthcare-related IE (70.5% vs. 36.3%, p<0.001) and Staphylococcus etiology (57.7% vs. 39.7%, p=0.001). Regarding evolution, patients with SOT had more frequent kidney function worsening (47.1% vs. 34.6%, p=0.02), septic shock (25.9% vs. 12.1%, p<0.001), sepsis (27.1% vs. 17.2%, p=0.02). Surgery indication (54.1% vs 66.3%, p=0.02) and surgery (32.9% vs. 46.3%, p=0.01) were less frequent in patients with SOT. We were unable to find significant differences in mortality: inhospital (30.6% vs. 25.6%, p=0.31), 1-year (38.8% vs. 31.9%, p=0.18). Conclusion IE in SOT patients has specific characteristics. Most of the cases are nosocomial and over 70% are hospital-or health care-related. Half have previously normal heart valves and almost 60% are due to Staphylococcus infections. Figure 1. Kaplan Meier survival curves for patients with and without solid organ transplantation (SOT). SOT: 56 kidney, 18 liver (2 combined with kidney), 8 heart, 3 lung. Funding Acknowledgement Type of funding source: None

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
George H.B. Greenhall ◽  
Matthew Robb ◽  
Chloe Brown ◽  
Rachel Johnson ◽  
Laurie A. Tomlinson ◽  
...  

PEDIATRICS ◽  
2011 ◽  
Vol 127 (4) ◽  
pp. 742-753 ◽  
Author(s):  
C. LaRosa ◽  
C. Glah ◽  
H. J. Baluarte ◽  
K. E. C. Meyers

Author(s):  
Manuel Martínez-Sellés ◽  
Maricela Valerio-Minero ◽  
María Carmen Fariñas ◽  
Hugo Rodríguez-Abella ◽  
María Luisa Rodríguez ◽  
...  

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S576-S576
Author(s):  
Emily Eichenberger ◽  
Michael M Dagher ◽  
Vance G Fowler ◽  
Jerome Federspiel

Abstract Background The prevalence and impact of infective endocarditis (IE) on organ transplant recipients is unknown. We used a large cohort of transplant recipients to assess the impact of IE on outcomes during index transplant hospitalization. Methods We used data from the 2013-2017 Nationwide Readmissions Database (NRD). Hospitalizations associated with solid organ transplantation procedures (heart, liver, kidney, lung, intestines, pancreas) were included. Outcomes included 60-day rates of mortality, ECMO deployment, thromboembolic events, length of stay, and inpatient costs. For data obtained October 2015 and later, rates of graft rejection and graft failure were also measured. Regression models, weighted to account for the NRD sample design, were used to model associations between outcomes and transplant procedure, adjusting for patient age, sex, facility characteristics, comorbid conditions, and organs transplanted. Results A total of 75,069 hospitalizations for organ transplantation, corresponding to a national estimate of 160,368, were included. A diagnosis of IE was associated with 416 (weighted estimate = 898). IE cases were less likely to be female (22.2% vs. 37.9%, p< 0.001), and had higher rates of underlying pulmonary disease. The most common organ transplanted in the hospitalization during which IE was diagnosed (allowing for multiple organs) was heart (84.5%) followed by kidney (8.9%) and liver (7.9%), (p< 0.001). IE was associated with higher mortality [adjusted relative risk (aRR): 1.70, 95% confidence interval (CI) (1.09, 2.66)], prolonged ventilation (aRR 1.32 [1.06, 1.65], 4.6 additional inpatient days (CI: 1.5, 7.6) and $28,300 more inpatient cost (CI: $12,000, $44,700) (Table). 60-Day Outcomes, Stratified by IE During Index Transplant Hospitalization Conclusion IE complicating hospitalization for organ transplantation is associated with higher rates of morbidity and mortality. IE during index transplant hospitalization occurs most frequently in heart transplant recipients. Understanding the high rate of IE in heart recipients in the early post-transplant period requires further study. Disclosures Vance G. Fowler, Jr., MD, MHS, Achaogen (Consultant)Actavis (Grant/Research Support)Advanced Liquid Logics (Grant/Research Support)Affinergy (Consultant, Research Grant or Support)Affinium (Consultant)Allergan (Grant/Research Support)Ampliphi Biosciences (Consultant)Basilea (Consultant, Research Grant or Support)Bayer (Consultant)C3J (Consultant)Cerexa (Consultant, Research Grant or Support)Contrafect (Consultant, Research Grant or Support)Cubist (Grant/Research Support)Debiopharm (Consultant)Destiny (Consultant)Durata (Consultant)Forest (Grant/Research Support)Genentech (Consultant, Research Grant or Support)Integrated Biotherapeutics (Consultant)Janssen (Consultant, Research Grant or Support)Karius (Grant/Research Support)Locus (Grant/Research Support)Medical Biosurfaces (Grant/Research Support)Medicines Co. (Consultant)Medimmune (Consultant, Research Grant or Support)Merck (Consultant, Research Grant or Support)NIH (Grant/Research Support)Novadigm (Consultant)Novartis (Consultant, Research Grant or Support)Pfizer (Grant/Research Support)Regeneron (Consultant, Research Grant or Support)Tetraphase (Consultant)Theravance (Consultant, Research Grant or Support)Trius (Consultant)xBiotech (Consultant)


2004 ◽  
Vol 78 ◽  
pp. 496
Author(s):  
E Ruttmann ◽  
C Legit ◽  
I Stelzmueller ◽  
O Chevtchik ◽  
H Antretter ◽  
...  

2011 ◽  
Vol 32 (8) ◽  
pp. 2363-2366 ◽  
Author(s):  
Shafieh Movassaghi ◽  
Mohsen Nasiri Toosi ◽  
Alireza Bakhshandeh ◽  
Fatemeh Niksolat ◽  
Zahra Khazaeipour ◽  
...  

Author(s):  
Emily M. Eichenberger ◽  
Michael Dagher ◽  
Matthew R. Sinclair ◽  
Stacey A. Maskarinec ◽  
Vance G. Fowler ◽  
...  

2018 ◽  
Vol 22 (5) ◽  
pp. e13217 ◽  
Author(s):  
Katharine Thomson ◽  
Kristine McKenna ◽  
Katherine Bedard-Thomas ◽  
Melisa Oliva ◽  
Patricia Ibeziako

Sign in / Sign up

Export Citation Format

Share Document